3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1
1
Status
Completed
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
3
CNS
2
Conditions
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Respiratory Tract Diseases
1
Neoplasms
1
Meningeal Carcinomatosis
1
Lung Neoplasms
1
Interventions
Temozolomide
299
Radiotherapy
219
Bevacizumab
139
Carboplatin
91
Cyclophosphamide
88
Etoposide
82
Filgrastim
72
Vincristine
69
Irinotecan
69
Magnetic Resonance Spectroscopy
64
Cisplatin
59
Radiation
58
Radiosurgery
52
Surgical Procedures, Operative
41
Peripheral Blood Stem Cell Transplantation
40
Topotecan
39
Doxorubicin
39
Lomustine
37
Carmustine
36
sargramostim
35
Granulocyte Colony-Stimulating Factor
35
Melphalan
34
Nivolumab
32
Chemotherapy, Adjuvant
32
Radiotherapy, Intensity-Modulated
29
Isotretinoin
29
Everolimus
29
Erlotinib Hydrochloride
27
Thiotepa
25
Vorinostat
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
AZD3759
×
CNS
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled
NCT02228369
2021-01-05
BLOOM
AstraZeneca
Phase 1
Completed
108 enrolled